RU-486 Suspension and Review Act of 2005

This bill would have suspended the Food and Drug Administration's (FDA) approval of mifepristone, a medication used for the medical termination of early pregnancies. It would have also prohibited the drug misoprostol from being labeled or marketed for use in ending pregnancies. Under this legislation, these restrictions would remain in place until the Government Accountability Office (GAO) conducted a full review to determine if the FDA’s original approval process followed all federal safety and regulatory requirements. If the review found the approval process was valid, the medication could then be reinstated for public use.